Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study
Marcus Hentrich(Red Cross Hospital), Christian Hoffmann(Hochschule für Angewandte Wissenschaften Kiel), Markus Bickel, Ivanka Krznaric, Annette Dieing, Margarida Brito(Instituto Português de Oncologia Francisco Gentil), Gedske Daugaard(Copenhagen University Hospital), Jürgen K. Rockstroh(University of Bonn), Massimiliano Berretta(University of Messina), Mark Bower(Chelsea and Westminster Hospital), Vindi Jurinović(Ludwig-Maximilians-Universität München), Pablo Maroto Rey(Hospital de Sant Pau), Klaus‐Peter Dieckmann(Asklepios Klinik Altona), Andrea Necchi(Vita-Salute San Raffaele University), David Pfister(American Society of Clinical Oncology), Florian Lesmeister(Krankenhaus vom Roten Kreuz), Albrecht Stoehr, Julia Heinzelbecker(Saarland University)
Cited by 2
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k